RE:RE:RE:RE:RE:RE:sSort or soluble sortilinLooks like it covers some antibodies as well.
Another aspect disclosed herein is an isolated antibody that targets Sortilin receptor.
[0023] Another aspect disclosed herein is an isolated antibody for use in targeting Sortilin receptor. Another aspect disclosed herein is an isolated antibody that binds at least 2, optionally at least 4 contiguous amino acid residues as shown in any one of SEQ ID NOs: 25-50, an analog thereof, or a fragment thereof.
[0024] Yet another aspect disclosed herein is a conjugate antibody having the formula of A’-(B)n,
jfm1330 wrote: Maybe it was posted here before by somebody else, but Thera filed for a patent specefically on the inhibition of vasculogenic mimicry. The patent covers not only TH1902, but a wide array of peptides and possible PDC. I would really like to hear what Beliveau and Marsolais would have to say about soluble sortilin.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020037434